Precision Peptide Company orders 20,000 thymosin alpha-1 transdermal patches
The order is tied to a planned commercial launch of the immune peptide in a transdermal patch format.
TR
By Tom Reyes · Markets Editor
Oct 7 14:11 ETSource: kalkine.ca
The wire
- 01The Precision Peptide Company has placed an order for 20,000 thymosin alpha-1 transdermal patches ahead of a commercial launch, according to the company announcement.
- 02Thymosin alpha-1 is tracked closely by clinicians and compounders, and a patch format would sit outside the injectable supply most practices currently use.
- 03No pricing, launch date, regulatory pathway or clinical data accompanied the announcement.
From the source
Read at kalkine.caThe Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Transdermal Patches for Commercial Launch
